Clinical Trial Update: Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated dasatinib in combination with the SMO inhibitor BMS-833923 for chronic myeloid leukemia and has completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BMS-833923
• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-05-20